Dopamine agonist therapy for Parkinson disease and pathological gambling

Parkinsonism and Related Disorders

Volumn 12, Issue 8, 2006, Pages 506-508

  Imamura, Akiko ^a   Uitti, Ryan J ^a   Wszolek, Zbigniew K ^a  

^a MAYO CLINIC   (United States)

Author keywords

Dopamine agonist; Levodopa; Parkinson disease; Pathological gambling

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE;

ADULT; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERSEXUALITY; INSOMNIA; MALE; MONOTHERAPY; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

CARBIDOPA; DOPAMINE AGONISTS; FEMALE; GAMBLING; HUMANS; LEVODOPA; MALE; MEDLINE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES;

EID: 33751232650     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.02.004     Document Type: Article

References (12)

1. Factor S.A., Molho E.S., Podskalny G.D., and Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 65 (1995) 115-138
2. Seedat S., Kesler S., Niehaus D.J., and Stein D.J. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 11 (2000) 185-186
3. Molina J.A., Sainz-Artiga M.J., Fraile A., Jimenez-Jimenez F.J., Villanueva C., Orti-Pareja M., and Bermejo F. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Movement Disord 15 (2000) 869-872
4. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Movement Disord 19 (2004) 433-437
5. Gschwandtner U., Aston J., Renaud S., and Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 24 (2001) 170-172
6. Driver-Dunckley E., Samanta J., and Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 (2003) 422-423
7. Avanzi M., Uber E., and Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 25 (2004) 98-101
8. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., and Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 (2005) 1377-1381 Epub 2005 Jul 11
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR™. 4th ed (2000), American Psychiatric Association, Washington, DC [p. 671-74]
10. Gerlach M., Double K., Arzberger T., Leblhuber F., Tatschner T., and Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110 (2003) 1119-1127
11. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., and Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347 (1990) 146-151
12. Reuter J., Raedler T., Rose M., Hand I., Glascher J., and Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 8 (2005) 147-148 Epub 2005 Jan 9